VSY Biotechnology GmbH

VSY Biotechnology GmbH gibt die Eröffnung eines neuen Büros in Dubai bekannt

vsybiotechnology — Mon, 15 Apr 2024 08:29:02 +0000

VSY Biotechnology GmbH gibt die Eröffnung eines neuen Büros in Dubai bekannt vsybiotechnology Mon, 04/15/2024 - 11:29

News Detail Paragraphs

News Text

Als führendes Unternehmen in der Branche der Biotechnologie freut sich VSY Biotechnology, die offizielle Eröffnung des neuen Büros in Dubai bekanntzugeben.

LEINFELDEN-ECHTERDINGEN, GERMANY, April 8, 2024

Als führendes Unternehmen in der Branche der Biotechnologie freut sich VSY Biotechnology GmbH, die offizielle Eröffnung des neuen Büros in Dubai bekanntzugeben. Diese strategische Expansion unterstreicht das Engagement des Unternehmens, Wachstum zu fördern, Kundenbeziehungen weiter auszubauen und die umfassenden Chancen der Regionen Naher Osten, Afrika und Südasien bestens zu nutzen.

Vertriebsleiter für den Nahen Osten und Afrika, Herr Ahmed Said, gibt an, dass man sich nach vielen strategischen Überlegungen für die Gründung von Dubai VSY entschieden habe und fährt fort wie folgt: „Während des Ausbaus unserer globalen Präsenz ist es von bedeutender Wichtigkeit, die diesem wichtigen Schritt zugrundeliegenden strategischen Gründe auch zum Ausdruck zu bringen. Zunächst bietet sich uns durch den Ausbau unserer Präsenz in Dubai aus strategischer Sicht eine Position auf einem sich stets weiterentwickelnden Markt, der zahlreiche Wachstumschancen birgt. Die Region Naher Osten, insbesondere Dubai, bietet Zugang zu vielfältigen Kundenstämmen und erleichtert internationale Kooperationen, indem die Region als ein sog. Tor zu entwicklungsfähigen Märkten fungiert.“

Dubai ist für seine strategische Lage bekannt und dient als bedeutender Knotenpunkt für die Verbindung wichtiger Märkte im Nahen Osten, in Afrika und Südasien. VSY Biotechnology GmbH will von diesen Vorteilen profitieren, um den Geschäftsausbau in diesen Regionen zu erleichtern und die Wachstumschancen zu erschließen.

Hinzu betont das Unternehmen die Bedeutung von Diversifikation und Risikominderung. VSY Biotechnology GmbH hat es zum Ziel, durch die Diversifikation ihrer geografischen Präsenz gegenüber regionalen wirtschaftlichen Schwankungen und geopolitischen Risiken widerstandfähiger zu sein. Darüber hinaus wird durch die unmittelbare Nähe zu regionalen Kunden eine individuellere und zeitnahe Kundenbetreuung sichergestellt, was wiederum eine Stärkung der Kundenbeziehungen zur Folge hat und sich auch positiv auf die Kundenzufriedenheit auswirkt.

Das Büro in Dubai stellt nicht nur eine physische Expansion dar, sondern dient auch als zentralen Punkt für Innovation und Talentakquise. Durch Einsatz talentierter Fachkräfte aus dem lokalen Pool und die Förderung der Kultur der Kreativität und Zusammenarbeit wird VSY Biotechnology GmbH in der Lage sein, zukunftsweisende Initiativen zu fördern und den Trends der Branche stets vorauszugehen.

„Die Gründung eines Büros in Dubai ist ein Zeichen unseres Engagements für globale Expansion und Diversifikation“, sagt Ahmet Said und fügt hinzu: Dadurch bietet sich uns die Möglichkeit, unsere Beziehungen zu bestehenden Kunden zu stärken, neue Partnerschaften zu begründen und unsere Markenpräsenz auf Schlüsselmärkten auszubauen. Darüber hinaus wird das Büro in Dubai als eine zentrale Stelle für Innovationen dienen, die beste Talente anziehen und strategische Partnerschaften und Netzwerkchancen fördern wird.“

Die Eröffnung des Büros in Dubai ist ein Beweis für das Engagement der VSY Biotechnology GmbH für nachhaltiges Wachstum, Innovation und Exzellenz. Dieses eng an den übergeordneten Geschäftszielen und der Vision des Unternehmens ausgerichtete Büro schafft eine solide Grundlage für den zukünftigen Erfolg auf dem globalen Markt.

The original content can be found at this URL: VSY Biotechnology GmbH gibt die Eröffnung eines neuen Büros in Dubai bekannt (einpresswire.com)

Opening of New Office in Dubai

vsybiotechnology — Mon, 15 Apr 2024 08:06:04 +0000

Opening of New Office in Dubai vsybiotechnology Mon, 04/15/2024 - 11:06

News Detail Paragraphs

News Text

VSY Biotechnology GmbH, a leading company in the biotechnology sector, is pleased to announce the official opening of its new office in Dubai.

LEINFELDEN-ECHTERDINGEN, GERMANY, April 8, 2024

VSY Biotechnology GmbH a leading company in the biotechnology sector, is pleased to announce the official opening of its new office in Dubai. This strategic expansion underscores the company's commitment to fostering growth, enhancing customer relationships, and tapping into the vast opportunities presented by the Middle East, Africa, and South Asia regions.

Ahmed Said, Sales Director of Middle East and Africa, stated that the decision to establish Dubai VSY is driven by multiple strategic considerations. "As we expand our global footprint, it's essential to articulate the strategic reasoning driving this significant move. Firstly, expanding our presence in Dubai strategically positions us in a thriving market with abundant opportunities for growth. The Middle East region, particularly Dubai, serves as a gateway to emerging markets offering access to a diverse customer base and facilitating international collaborations.”

Dubai is recognized for its strategic location, serving as a vital hub that connects key markets across the Middle East, Africa, and South Asia. VSY Biotechnology GmbH aims to leverage this advantage to facilitate business expansion and unlock growth opportunities in these regions.

The company also highlights the importance of diversification and risk mitigation. By diversifying its geographical presence, VSY Biotechnology GmbH aims to enhance resilience against regional economic fluctuations and geopolitical risks. Moreover, the proximity to clients in the region will allow for more personalized and timely support, ultimately strengthening client relationships and improving customer satisfaction.

The Dubai office is not just a physical expansion but also serves as a hub for innovation and talent acquisition. By tapping into the local pool of skilled professionals and fostering a culture of creativity and collaboration, VSY Biotechnology GmbH is set to drive forward-thinking initiatives and stay ahead of industry trends.

"Establishing an office in Dubai demonstrates our commitment to global expansion and diversification. It enables us to strengthen relationships with existing clients, attract new partnerships, and enhance our brand presence in key markets. Furthermore, the Dubai office will act as a center for innovation, attracting top talent and fostering strategic partnerships and networking opportunities," Ahmed Said stated.

The opening of the Dubai office is a testament to VSY Biotechnology GmbH's commitment to sustainable growth, innovation, and excellence. It aligns closely with the company's overarching business goals and vision, setting a solid foundation for future success in the global market.

The original content can be found at this URL: VSY Biotechnology GmbH Announces Opening of New Office in Dubai (einpresswire.com)

Reviscon Mono 2 % von VSY Biotechnology erhält die Zulassung von Health Canada für Osteoarthritis

vsybiotechnology — Thu, 28 Mar 2024 11:35:01 +0000

Reviscon Mono 2 % von VSY Biotechnology erhält die Zulassung von Health Canada für Osteoarthritis vsybiotechnology Thu, 03/28/2024 - 14:35

News Detail Paragraphs

News Text

VSY Biotechnology GmbH meldet, dass Health Canada Reviscon Mono 2% (2,4 ml), eine Injektionslösung gegen Arthroseschmerzen in Synovial-Gelenken, zugelassen hat.

LEINFELDEN-ECHTERDINGEN, GERMANY, March 19, 2024

/EINPresswire.com/ -- VSY Biotechnology GmbH freut sich bekannt zu geben, dass Health Canada Reviscon Mono 2 % (2,4 ml) eine viskoelastische Natriumhyaluronat-Lösung zur Einzelinjektion, die zur Vorbeugung von Schmerzen und Bewegungseinschränkungen im Zusammenhang mit Arthrose in allen Synovial-Gelenken entwickelt wurde, zugelassen hat.

Reviscon Mono 2,0 % ist eine viskoelastische Natriumhyaluronat-Lösung zur intraartikulären Injektion, die in einer 2,4-ml-Einweg-Glasspritze erhältlich ist. Jeder Milliliter Reviscon Mono enthält 20,0 mg Natriumhyaluronat sowie Natriumchlorid, Dinatriumhydrogenphosphat, Natriumdihydrogenphosphat und Wasser für Injektionszwecke, die sorgfältig zusammengestellt wurden, um die Symptome von Arthrose zu lindern.

Die Zulassung von Reviscon Mono durch Health Canada folgt auf die erfolgreiche Markteinführung in Vietnam Anfang dieses Jahres als Teil der Reviscon IA-HA-Produktreihe. Dies stellt einen bedeutenden Meilenstein für VSY Biotechnology dar, da das Unternehmen weiterhin seine Mission, die Verfügbarkeit innovativer Osteoarthritis-Behandlungen weltweit zu erweitern, verfolgt.

“Nach der Marktzulassung der Reviscon IA-HA-Reihe in Vietnam Anfang des Jahres stellt die Zulassung unseres bahnbrechenden Produkts Reviscon Mono durch Health Canada einen wichtigen nächsten Schritt dar, da wir die geografische Reichweite unserer neuartigen Osteoarthritis-Behandlungstherapie im Asiatisch-Pazifischen Raum und in Nord-, Mittel- und Südamerika weiter ausbauen. Unser Ziel ist es, unser Reviscon-Portfolio, insbesondere Reviscon Mono, als weltweit führendes Einzelinjektionsprodukt auf dem Markt zu etablieren“, sagte Florian Früh, Global Business Development Manager Orthopaedics bei VSY Biotechnology und leitender MedTech-Manager mit 25-jähriger Erfahrung in der internationalen Strategie und Vermarktung medizinischer Produkte und Dienstleistungen.

Diese Zulassung stärkt nicht nur die Position von VSY Biotechnology auf dem globalen Orthopädiemarkt, sondern zeigt auch das Engagement des Unternehmens, die Lebensqualität von Menschen mit Arthrose durch innovative Behandlungsmöglichkeiten zu verbessern.

Andreas C. Kuehnel, Board Member, VSY Biotechnology GmbH

The original content can be found at this URL: Reviscon Mono 2 % von VSY Biotechnology erhält die Zulassung von Health Canada für Osteoarthritis (einpresswire.com)

VSY Biotechnology’s Reviscon Mono 2% Receives Health Canada Approval for Osteoarthritis

vsybiotechnology — Thu, 28 Mar 2024 11:21:16 +0000

VSY Biotechnology’s Reviscon Mono 2% Receives Health Canada Approval for Osteoarthritis vsybiotechnology Thu, 03/28/2024 - 14:21

News Detail Paragraphs

News Text

VSY Biotechnology announced Health Canada's approval of Reviscon Mono 2% (2.4 ml), a one-time injectable solution for osteoarthritis pain and mobility issues.

LEINFELDEN-ECHTERDINGEN, GERMANY, March 19, 2024

VSY Biotechnology GmbH is pleased to announce that Health Canada has approved Reviscon Mono 2% (2.4 ml), a single-injection viscoelastic sodium hyaluronate solution designed to prevent pain and motion limitation associated with osteoarthritis in all synovial joints.

Reviscon Mono 2.0% is a viscoelastic sodium hyaluronate solution for intra-articular injection, presented in a 2.4 ml single-use glass syringe. Each milliliter of Reviscon Mono contains 20.0 mg of sodium hyaluronate, alongside sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate, and water for injection, meticulously formulated to provide relief from the symptoms of osteoarthritis.

The approval of Reviscon Mono by Health Canada follows its successful market launch in Vietnam earlier this year, as part of the Reviscon IA-HA product range. This marks a significant milestone for VSY Biotechnology as it continues to pursue its mission of broadening the availability of innovative osteoarthritis treatments across the globe.

“Following market approval in Vietnam for the Reviscon IA-HA range earlier this year, Health Canada approval for our trailblazer product Reviscon Mono marks an important next step as we continue to expand the geographic reach of our novel osteoarthritis treatment therapy in Asia Pacific and the Americas. We aim to establish our Reviscon portfolio, especially Reviscon Mono, as the premier single-injection product on the market worldwide,” said Florian Früh, VSY Biotechnology's Global Business Development Manager Orthopedics and a Senior MedTech executive with 25 years of experience in international strategy and commercialization of medical products and services.

This approval not only strengthens VSY Biotechnology's position in the global orthopedics market but also demonstrates the company’s commitment to improving the quality of life for individuals suffering from osteoarthritis through innovative treatment options.

Andreas C. Kuehnel, Board Member, VSY Biotechnology GmbH

The original content can be found at this URL: VSY Biotechnology’s Reviscon Mono 2% Receives Health Canada Approval for Osteoarthritis (einpresswire.com)

VSY Biotechnology wird auf dem bevorstehenden ESCRS-Wintertreffen sein neuartiges ophthalmologisches Produkt Enova Maestro IOL

vsybiotechnology — Thu, 22 Feb 2024 13:43:53 +0000

VSY Biotechnology wird auf dem bevorstehenden ESCRS-Wintertreffen sein neuartiges ophthalmologisches Produkt Enova Maestro IOL vsybiotechnology Thu, 02/22/2024 - 16:43

News Detail Paragraphs

News Image

News Text

VSY Biotechnology GmbH gab seine strategische Zusammenarbeit mit Great Place to Work®.

Als zweitgrößter legaler Hersteller von IOLs in Deutschland ist es unsere Vision, ein anerkannter Vorreiter bei der Förderung einer „Great Place to Work“-Kultur zu werden.”— Mila Kolarova, HR Business Partner bei VSY Biotechnology GmbH

LEINFELDEN-ECHTERDINGEN, GERMANY, February 22, 2024

/EINPresswire.com/ -- VSY Biotechnology GmbH, ein führendes Biotechnologieunternehmen mit Sitz in Leinfelden-Echterdingen, Deutschland, gab seine strategische Zusammenarbeit mit Great Place to Work®, der globalen Autorität für Arbeitsplatzkultur und Mitarbeitererfahrung, bekannt.

Diese Partnerschaft unterstreicht das Engagement von VSY Biotechnology für die Förderung eines unterstützenden, integrativen und dynamischen Arbeitsumfelds mit dem Ziel, in diesem Jahr das prestigeträchtige Great Place to Work-Zertifikat zu erhalten und diese Anerkennung in den kommenden Jahren aufrechtzuerhalten.

Die Initiative von VSY Biotechnology mit Great Place to Work® umfasst einen umfassenden Bewertungsprozess, einschließlich Mitarbeiterbefragungen und einem Kulturaudit, um Stärkebereiche und Wachstumschancen zu identifizieren. Die aus dieser Zusammenarbeit gewonnenen Erkenntnisse werden in gezielte Strategien zur Verbesserung des Wohlbefindens der Mitarbeiter, zur Förderung der beruflichen Entwicklung und zum Aufbau eines geschlossenen, leistungsstarken Teams einfließen.

Mila Kolarova, HR Business Partner bei VSY Biotechnology GmbH, sagte: „Als zweitgrößter legaler Hersteller von IOLs in Deutschland ist es unsere Vision, ein anerkannter Vorreiter bei der Förderung einer „Great Place to Work“-Kultur zu werden. Wir setzen uns dafür ein, ein Umfeld zu schaffen, in dem sich jedes Teammitglied geschätzt, unterstützt und befähigt fühlt, sein volles Potenzial auszuschöpfen. Indem wir effektive Führung, sinnvolle Werte und eine tiefe Vertrauensbasis in den Vordergrund stellen, wollen wir einen Arbeitsplatz schaffen, an dem jeder sein Bestes geben kann. Unser Fokus auf Agilität, Veränderungsmanagement, Innovation und Führungsqualität stellt sicher, dass wir immer einen Schritt voraus sind und uns an die sich verändernden Bedürfnisse unserer Belegschaft anpassen.“

„Durch unser Engagement für das Wohlbefinden, den Respekt, die Glaubwürdigkeit und die Fairness unserer Mitarbeiter streben wir danach, die Kriterien für die „Great Place to Work“-Zertifizierung nicht nur zu erfüllen, sondern zu übertreffen. Wir glauben, dass die Erlangung dieser Zertifizierung nicht nur unser Engagement für die Zufriedenheit und den Erfolg unserer Mitarbeiter bestätigt, sondern auch ein Beweis für unser kontinuierliches Streben nach Exzellenz ist. Gemeinsam bauen wir eine Kultur auf, in der jeder Einzelne stolz darauf ist, Teil unseres Teams zu sein, und in der unsere gemeinsamen Anstrengungen Innovation, Wachstum und Erfolg für unser Unternehmen und unsere Mitarbeiter vorantreiben“, erklärte Mila Kolarova weiter.

Andreas Kühnel
VSY Biotechnology

VSY Biotechnology Partners with Great Place to Work® to Foster Exceptional Workplace Culture (einpresswire.com)

VSY Biotechnology Partners with Great Place to Work® to Foster Exceptional Workplace Culture

vsybiotechnology — Thu, 22 Feb 2024 13:17:10 +0000

VSY Biotechnology Partners with Great Place to Work® to Foster Exceptional Workplace Culture vsybiotechnology Thu, 02/22/2024 - 16:17

News Detail Paragraphs

News Image

News Text

VSY Biotechnology GmbH, a leading biotechnology company, announced its strategic collaboration with Great Place to Work®.

By prioritizing effective leadership, meaningful values, and a deep foundation of trust, we aim to cultivate a workplace where everyone can contribute their best.”— Mila Kolarova, HR Business Partner at VSY Biotechnology GmbH

LEINFELDEN-ECHTERDINGEN, GERMANY, February 22, 2024

/EINPresswire.com/ -- VSY Biotechnology GmbH, a leading biotechnology company based in Leinfelden-Echterdingen, Germany, announced its strategic collaboration with Great Place to Work®, the global authority on workplace culture and employee experience.

This partnership underscores VSY Biotechnology's commitment to fostering a supportive, inclusive, and dynamic work environment, with the aim of being awarded the prestigious Great Place to Work certificate this year and sustaining this recognition in the years to come.

VSY Biotechnology's initiative with Great Place to Work® involves a comprehensive evaluation process, including employee surveys and a cultural audit, to identify areas of strength and opportunities for growth. The insights gained from this collaboration will inform targeted strategies to enhance employee well-being, promote professional development, and build a cohesive, high-performing team.

Mila Kolarova, HR Business Partner at VSY Biotechnology GmbH, said: “As the second largest legal manufacturer of IOLs in Germany, our vision is to become a recognized leader in fostering a 'Great Place to Work' culture. We are committed to creating an environment where every team member feels valued, supported, and empowered to reach their full potential. By prioritizing effective leadership, meaningful values, and a deep foundation of trust, we aim to cultivate a workplace where everyone can contribute their best. Our focus on agility, change management, innovation, and leadership excellence ensures that we stay ahead of the curve and adapt to the evolving needs of our workforce.”

“Through our dedication to employee wellbeing, respect, credibility, and fairness, we strive to not only meet but exceed the criteria for 'Great Place to Work' certification. We believe that achieving this certification not only validates our commitment to our employees' happiness and success but also serves as a testament to our continuous pursuit of excellence. Together, we are building a culture where every individual is proud to be a part of our team, and where our collective efforts drive innovation, growth, and success for our company and our people,” Mila Kolarova further stated.

Andreas C. Kuehnel, VSY Biotechnology GmbH

The original content can be found at this URL: VSY Biotechnology Partners with Great Place to Work® to Foster Exceptional Workplace Culture (einpresswire.com)

VSY Biotechnology stellt Enova Maestro® IOL auf dem ESCRS-Wintertreffen vor

vsybiotechnology — Fri, 16 Feb 2024 06:38:24 +0000

VSY Biotechnology stellt Enova Maestro® IOL auf dem ESCRS-Wintertreffen vor vsybiotechnology Fri, 02/16/2024 - 09:38

News Detail Paragraphs

News Image

News Text

VSY Biotechnology wird auf dem bevorstehenden ESCRS-Wintertreffen sein neuartiges ophthalmologisches Produkt Enova Maestro® IOL.

“Unlike conventional lenses with overlapping diffraction patterns, VSY Biotechnology’s patented SVT® eliminates sharp edges, thereby reducing halo and glare for an enhanced visual experience.”— Andreas C. Kuehnel, Board Member at VSY Biotechnology

LEINFELDEN-ECHTERDINGEN, GERMANY, February 15, 2024

EINPresswire.com/ -- VSY Biotechnology GmbH, ein führendes Biotechnologieunternehmen, wird auf dem bevorstehenden ESCRS-Wintertreffen sein neuartiges ophthalmologisches Produkt Enova Maestro® - Sinusoidal Trifocal Toric Preloaded IOL vorstellen. Diese mit Spannung erwartete Veranstaltung, die vom 15. bis 18. Februar 2024 im Congress Center Messe Frankfurt in Deutschland stattfinden soll, wird mit der Einführung ihres neuen Produkts einen bedeutenden Meilenstein für VSY Biotechnology darstellen.

Enova Maestro® besteht zu 100 % aus glitzerfreiem, hydrophobem Acrylmaterial und zeichnet sich durch seine Fähigkeit, bei allen Lichtverhältnissen eine außergewöhnliche Sicht auf weite, mittlere und nahe Entfernungen zu bieten, aus. Mit einer maximalen Lichtdurchlässigkeit von 93,5 % auf die Netzhaut gewährleistet Enova Maestro® optimale Sehergebnisse für Patienten. Robin Ege, Global Produkt-Manager bei VSY Biotechnology, kommentierte: “Enova Maestro® bietet eine hervorragende Sicht für weite, mittlere und nahe Entfernungen bei allen Lichtverhältnissen sowie eine effektive und maximale Lichtübertragung auf die Netzhaut. Sein glitzerfreies Material erhöht seine Zuverlässigkeit und Leistung zusätzlich.“

Ein weiteres wichtiges Merkmal des Enova Maestro® ist die Integration der Sinusoidal Vision Technology® (SVT®), einem einzigartigen optischen Design, das weiche Grate nutzt, um eine nahtlose Sicht in allen Entfernungen und bei allen Lichtverhältnissen zu ermöglichen. Andreas Kuehnel, Vorstandsmitglied von VSY Biotechnology, sagte: “Im Gegensatz zu herkömmlichen Linsen mit überlappenden Beugungsmustern eliminiert das patentierte SVT® von VSY Biotechnology scharfe Kanten und reduziert dadurch Schein und Blendung für ein verbessertes Seherlebnis.“ Mit all diesen Qualitäten ist Enova Maestro bereit, den Bereich der Augenheilkunde zu revolutionieren.“

Im Vorfeld der Einführung von Enova Maestro® organisiert VSY Biotechnology am 15. Februar ein hochkarätiges Key Opinion Leader (KOL)-Dinner. Der renommierte Augenarzt Dr. Florian Kretz wird einen Vortrag über die technischen Qualitäten und Vorteile des Enova Maestro® halten. Die Teilnehmer erwartet einen umfassenden Überblick über dieses revolutionäre Intraokularlinsensystem (IOL), das sein innovatives Design und seine beispiellose Leistung hervorhebt.

VSY Biotechnology lädt alle Teilnehmer des ESCRS-Wintertreffens ein, ihren Stand auf der C30 zu besuchen, um mehr über das Enova Maestro® – Sinusoidal Trifocal Toric Preloaded IOL System zu erfahren und seine transformativen Auswirkungen auf die Augenheilkunde zu erkunden.

Andreas Kühnel
VSY Biotechnology GmbH

Dieser Nachrichteninhalt wird aus der Nachrichtenquelle germanhealthreview.com generiert

VSY Biotechnology to Launch Enova Maestro® IOL at ESCRS Winter Meeting

vsybiotechnology — Thu, 15 Feb 2024 08:16:38 +0000

VSY Biotechnology to Launch Enova Maestro® IOL at ESCRS Winter Meeting vsybiotechnology Thu, 02/15/2024 - 11:16

News Detail Paragraphs

News Image

News Text

VSY Biotechnology GmbH is set to launch its novel ophthalmic product Enova Maestro® - Sinusoidal Trifocal Toric Preloaded IOL at the ESCRS Winter Meeting.

“Unlike conventional lenses with overlapping diffraction patterns, VSY Biotechnology’s patented SVT® eliminates sharp edges, thereby reducing halo and glare for an enhanced visual experience.”— Andreas C. Kuehnel, Board Member at VSY Biotechnology

Published 2:16 PM GMT+3, February 14, 2024

LEINFELDEN-ECHTERDINGEN, GERMANY, February 14, 2024 / EINPresswire.com / -- VSY Biotechnology GmbH, a leading biotechnology company, is set to launch its novel ophthalmic product Enova Maestro® - Sinusoidal Trifocal Toric Preloaded IOL at the upcoming ESCRS Winter Meeting. Scheduled to take place from February 15 to 18, 2024, at the Congress Centre Messe Frankfurt in Germany, this eagerly anticipated event will mark a significant milestone for VSY Biotechnology with the launch of its new product.

Composed of 100% glistening-free hydrophobic acrylic material, Enova Maestro® stands out for its ability to deliver exceptional vision across far, intermediate, and near distances under all lighting conditions. Boasting a maximum light transmission to the retina of 93.5%, Enova Maestro® ensures optimal visual outcomes for patients. Robin Ege, Global Product Manager at VSY Biotechnology, commented, “Enova Maestro® offers excellent vision for far, intermediate, and near distances in all light conditions, along with effective and maximum light transmission to the retina. Its glistening-free material further enhances its reliability and performance.”

Another key feature of the Enova Maestro® is the incorporation of Sinusoidal Vision Technology® (SVT®), a unique optical design that utilizes soft ridges to provide seamless vision at all distances for all light conditions. Andreas Kuehnel, Board Member of VSY Biotechnology, said, “Unlike conventional lenses with overlapping diffraction patterns, VSY Biotechnology’s patented SVT® eliminates sharp edges, thereby reducing halo and glare for an enhanced visual experience. With all these qualities, Enova Maestro is poised to revolutionize the field of ophthalmology.”

In anticipation of the Enova Maestro® launch, VSY Biotechnology is organizing a distinguished Key Opinion Leader (KOL) dinner on February 15. Renowned ophthalmologist Dr. Florian Kretz will deliver a speech on the technical qualities and advantages of the Enova Maestro®. Attendees can expect a comprehensive overview of this revolutionary intraocular lens (IOL) system, highlighting its innovative design and unparalleled performance.

VSY Biotechnology invites all attendees of the ESCRS Winter Meeting to visit their booth at C30 to learn more about the Enova Maestro® - Sinusoidal Trifocal Toric Preloaded IOL System and explore its transformative impact on ophthalmic care.

Andreas C. Kuehnel, VSY Biotechnology GmbH

This news content is generated from the news source/outlet The Associated Press

The original content can be found at this URL:

VSY Biotechnology to Launch Enova Maestro® IOL at ESCRS Winter Meeting | AP News

AGB Content

vsybiotechnology — Thu, 04 Jan 2024 23:16:34 +0000

AGB Content vsybiotechnology Fri, 01/05/2024 - 02:16

Description

Allgemeine Geschäftsbedingungen der VSY Biotechnology GmbH:

ALLGEMEINE GESCHÄFTSBEDINGUNGEN
GENERAL TERMS AND CONDITIONS - AGB English Version

Page Link

/agb

GENERAL TERMS AND CONDITIONS

vsybiotechnology — Thu, 04 Jan 2024 22:39:26 +0000

GENERAL TERMS AND CONDITIONS vsybiotechnology Fri, 01/05/2024 - 01:39

Description

GENERAL TERMS AND CONDITIONS

These General Terms and Conditions apply to all business relations between VSY BiotechnologyGmbH (hereinafter referred to as "VSY") and customers who are entrepreneurs in the sense of § 14 BGB.

1. Applicable Law

1. General

These General Terms and Conditions of Sale and Delivery shall apply to all contracts concluded between VSY Biotechnology GmbH, Leinfelden-Echterdingen, (hereinafter also referred to as "VSY") and the customer as well as to all other deliveries and services. They shall also apply to all future business relations with the customer, even if they are not expressly agreed again. With the placing of an order, at the latest with the receipt of the goods or the use of the service, the customer accepts the following conditions. Conditions of the customer, which VSY does not expressly recognize, are not binding for VSY, even if VSY does not expressly object. Only authorized signatories and managing directors of VSY are authorized to make changes to a contract or agreements deviating from these terms and conditions in writing.

2. Offers and Conclusion of Contract

Offers from VSY are subject to change and non-binding. The customer is bound to his order (purchase order) 8 weeks from receipt of the same by VSY. A contract is concluded when VSY confirms acceptance of the offer in writing or executes the order. The issuance of the invoice is equivalent to the order confirmation. In the interest of further technical and medical development, VSY reserves the right to make design and execution changes even after acceptance of the order, insofar as this is reasonable for the customer.

3. Prices

The price valid at the time of the conclusion of the contract shall apply, errors and misprints excepted, plus statutory value added tax. Prices are shown in Euro. If VSY has entered into a Fixed Price Agreement with the Buyer, VSY shall be entitled to adjust the agreed price accordingly if there is a period of at least four months between the placing of the order and the date of delivery and if during this period there has been a significant change either in the cost of wages, transport and/or materials of VSY or in the selling price of VSY's suppliers or if there has been a significant change in the amount of levies to be paid by VSY due to statutory regulations or ordinances and these changes have resulted in a changed cost or levy burden for VSY at the end of the 4-month period. Simultaneous increases and decreases in the various costs and charges shall be mutually offset in this calculation. Only if a significant change has then occurred in the result, VSY is entitled to a corresponding price adjustment right with disclosure of the cost development. In this case, the customer can withdraw from the contract extraordinarily.

4. Payments/Delay in Payment/Offset

Our invoices are due within 30 days from the invoice date without deductions.

VSY may refuse to accept payment instructions, checks and bills of exchange at any time. If, then the acceptance is only on account of performance. All related bank charges shall be borne by the customer. Fulfillment occurs only when the debt amount is credited to the account of VSY. Reductions for postage, transfer or similar fees are excluded. VSY is entitled to demand advance payment at any time, even for partial deliveries. If the customer is in arrears with payments, VSY is entitled to charge interest on arrears of up to 10% above the base interest rate according to § 247 BGB. VSY reserves the right to assert further rights and other claims for damages in this case. The customer is entitled to prove to VSY a lower damage caused by delay. If the customer defaults on a payment obligation that amounts to at least 15% of all VSY's claims against the customer, including those that are not due, all VSY's claims shall become due for payment in total. All payment deferrals - even in the case of acceptance of a bill of exchange - end. VSY is entitled to make the delivery of goods dependent on an advance payment in the amount of the respective value of the goods during the period of default in the aforementioned sense. VSY may stop further processing of the order and make its continuation dependent on the customer providing security in the amount of the total order value. If the customer does not provide a corresponding security within a reasonable period to be set by VSY, VSY is entitled to withdraw from the contract and to claim damages instead of performance. If the customer defaults on a payment obligation that does not reach the aforementioned amount, the statutory provisions alone shall apply. The buyer may only offset claims that are undisputed, legally established or disputed but ready for decision. He shall only be entitled to a right of retention insofar as it is based on the same contractual relationship. VSY is entitled to assign the claims arising from its business relations.

5. Delivery

Delivery dates are only binding if they are confirmed. Freight, postage, packaging and insurance, also for partial deliveries, will be charged separately. In the event of our failure to deliver or a delay in delivery, the customer may declare his withdrawal from the contract after a reasonable period of grace to be determined, which shall not be less than one month. The assertion of a claim for damages is limited in accordance with No. 13. of these GTC. Events due to force majeure, in particular also due to strikes, lockouts, operational disruptions and lack of suitable labor, raw or auxiliary materials of any kind, traffic disruptions, etc., shall entitle VSY to postpone delivery for the duration of the hindrance and/or to withdraw from the contract if delivery becomes impossible. Partial deliveries can be made by VSY and must be accepted by the customer.

6. Transfer of Risk and Transport

Unless otherwise agreed, VSY shall determine the means of transport and the transport route at its own discretion. The risk is transferred to the customer when the goods leave the factory or warehouse of VSY and have been handed over to a transport company not affiliated with VSY, but at the latest upon delivery. This also applies to partial deliveries. VSY is not obliged to take out transport insurance. In the event of damage to or loss of the goods in transit, the customer shall immediately notify the carrier in writing and inform VSY thereof.

7. Retention of Title

Delivered goods remain the property of VSY until full payment of the purchase price and settlement of all claims arising from the business relationship. Any processing or transformation of the goods subject to retention of title by the customer shall always be carried out for VSY. If the goods subject to retention of title are processed or mixed with other items not belonging to VSY, VSY shall acquire co-ownership of the new item in the ratio of the value of the goods subject to retention of title to the other processed items at the time of processing or mixing. If the customer's item is to be regarded as the main item, the customer shall transfer co-ownership to VSY on a pro rata basis. The customer shall then store the item free of charge for VSY.

Upon request, the buyer is obliged to inform VSY of the extent and location of the reserved goods in his possession. The purchaser may resell goods subject to retention of title in the ordinary course of business subject to retention of title. Without VSY's approval, the customer may not pledge or assign goods subject to retention of title by way of security. The customer hereby assigns to VSY by way of security all claims arising from the resale or any other legal reason (e.g. insurance, tort) with regard to the goods subject to retention of title, including all balance claims from the current account. VSY revocably authorizes the customer to collect the claims assigned to VSY for the account of VSY in his own name. VSY may revoke the authority to resell the goods subject to retention of title as well as to collect the claim assigned to VSY if it becomes apparent that VSY's claim to consideration is endangered by the customer's lack of ability to pay. VSY is then entitled to demand information about the consignee, to inform the consignee of the subrogation and to collect claims of the customer against the consignee. If the customer in case of default of payment does not settle all due claims after request, VSY is entitled, without prejudice to further rights, to demand immediate surrender of all goods subject to retention of title which are in its ownership. The customer is not entitled to retention in this case. In such a case, the customer already now grants VSY the irrevocable right to immediately collect the goods subject to retention of title and for this purpose to enter the customer's business and storage premises without hindrance during normal business hours. VSY clarifies that the exercise of these rights is for security purposes only and does not constitute a rescission of the contract. If the value of the securities given to VSY exceeds the total amount of VSY's claims by more than 20%, the customer may demand the release of securities at VSY's discretion.

8. Notices of Defects

(this provision does not apply to consumers within the meaning of § 13 of the German Civil Code).

The customer is obliged to inspect delivered goods immediately upon receipt. VSY will only consider complaints if the customer notifies VSY of them in writing without delay. The customer must immediately notify us in writing of any defects that are not obvious. Decisive for compliance with the deadlines is the receipt of the declaration by VSY. If the aforementioned deadlines are missed, the goods are considered approved and warranty claims are excluded. Notices of defects do not affect the due date of the purchase price.

In the event of loss or damage to the delivery/goods in transit, it is necessary to send a certificate from the relevant transport company.

9. Warranty

In principle, the customer is entitled to the statutory warranty rights. The limitation period for these warranty rights is one year if the customer is an entrepreneur, but two years if the customer is a consumer.

Intraocular lenses (IOL) that have become unsterile must not be sterilized independently. In this case the warranty right expires.

The warranty expires if third parties carry out interventions or repairs without express permission. VSY does not warrant for defects caused by improper handling by the buyer, especially during transport and storage, and improper use of the item. The agreement of quality characteristics as well as the assumption of quality and durability guarantees require express agreement. If a delivery of goods is defective, VSY shall in principle only be obliged to remedy the defect or to deliver a replacement free of defects (subsequent performance). The buyer is entitled to other claims for defects, in particular the right to withdraw from the contract or to reduce the purchase price, only if VSY does not remedy the defect or deliver defect-free goods within a reasonable period set by the buyer. VSY is not obligated to subsequent performance and/or warranty as long as the purchaser is in default with the fulfillment of essential contractual obligations on his part. This shall not apply if the Buyer is entitled to a right to refuse performance or a right of retention. The Buyer may withhold payment due to defects or assert other rights to refuse performance only to the extent that the amount of the withheld payment is in reasonable proportion to the extent of the defect.

The type of supplementary performance chosen by the customer without prejudice to § 275 paragraph 2 and 3 of the German Civil Code (BGB) can be refused by VSY if it is only possible with disproportionately high costs. In this case, the customer's claim shall be limited to the other type of subsequent performance. VSY's right to refuse subsequent performance due to disproportionately high costs even under these conditions remains unaffected. If the supplementary performance fails or if VSY is not willing or able to do so, the customer may withdraw from the contract or reduce the purchase price. Subsequent performance shall be deemed to have failed after the second unsuccessful attempt, unless the nature of the item or the defect or other circumstances in particular indicate otherwise. However, in the event of only a minor breach of contract, in particular in the event of only minor defects, the customer shall not be entitled to withdraw from the contract. If the customer also asserts a claim for damages due to a defect in title or quality, the customer shall only be entitled to compensation in accordance with Section 13 of these GTC. Warranty obligations shall not exist if the defects that have occurred are causally related to the fact that the customer has not reported a defect in accordance with Section 8 and has not immediately given the opportunity for subsequent performance or if the subject matter of the contract has been improperly handled or overused, operating or maintenance instructions from us have not been followed by the customer or the subject matter of the contract has previously been repaired, maintained or serviced in a business other than ours or one authorized by us or parts have been installed in the subject matter of the contract or parts or accessories have been used with the subject matter of the contract the use of which we have not approved or the subject matter of the contract has been modified by the customer in any other way not approved by us. These provisions shall not apply to guarantees of quality and durability or in the event of fraudulent concealment of a defect or fraudulent pretense of a non-existent quality. In the event that a guarantee is not complied with, VSY's liability shall be limited to compensation for foreseeable and direct damage that was precisely intended to be prevented by the assumption of the guarantee; unless compensation also for further damage is expressly covered by the guarantee. The assignment of warranty claims requires the express prior consent of VSY.

10. Return of Goods Free of Defects

A right to return goods is generally excluded. If a return is nevertheless made in individual cases, this shall only apply to new and originally packaged goods. Returns always require prior agreement with VSY. Goods which VSY no longer carries in its program or which were manufactured or procured at the special request of the customer will not be taken back even in exceptional cases. If VSY agrees to take back goods, 20% of the value of the goods shall be charged as a review and handling fee.

11. Liability

(1) We shall be liable in accordance with the statutory provisions, but our liability for damages shall be limited as follows:

a) In the event of simple negligence, liability shall only be assumed for injury to life, limb and health.

b) In the event of intent on the part of ordinary vicarious agents, or gross negligence on the part of legal representatives, employees or vicarious agents, liability shall be limited to the foreseeable, typically occurring damage. The limitation does not apply to damages resulting from injury to life, body or health. It also does not apply to consumers.

c) In the event of a breach of a cardinal obligation, we shall be liable in deviation from lit. a) also in the case of simple negligence, but limited as under b). A cardinal obligation is understood to be an obligation the fulfillment of which makes the proper execution of the contract possible in the first place and on the fulfillment of which the contractual partner may regularly rely.

12. The mandatory provisions of the Product Liability Act and liability in the event of a warranty shall
remain unaffected. In the event of any other breach of duty, in particular culpa in contrahendo,
default or tort, we shall not assume any further liability than provided for above.

13. Our legal representatives, officers and ordinary employees are not liable further than ourselves.

14. Confidentiality and Trademark Protection

Offer, sales and other documents including image, sound and other data carriers may not be handed over to third parties or unauthorized persons, neither in the original nor in copy, nor otherwise used in a manner detrimental to our interests without our approval. Furthermore, our conditions granted in an offer, in particular prices, may not be passed on to third parties, whether in writing or verbally. The customer is not allowed to use or otherwise use the name "VSY", the trademark "VSY", the logo and other signs or any designations of VSY without our written permission.

15. Resignation

Until the goods are shipped, we shall be entitled to withdraw from the contract if the customer is in breach of contract to a not inconsiderable extent, if its financial situation deteriorates significantly or if the circumstances on which the contract is based change significantly.

16. Foreign Deliveries

Due to existing foreign contracts, products purchased from us may only be exported with our express written permission.

17. Place of Performance and Jurisdiction

The place of performance for all claims of a contractual and non-contractual nature shall be Leinfelden-Echterdingen. German law shall apply exclusively to deliveries and services also abroad or to foreign customers and to contracts of all kinds. The provisions of the UN Convention on Contracts for the International Sale of Goods (CISG) as well as the reference standards of German private international law with regard to contractual relationships under the law of obligations are excluded. If the customer is a merchant or a legal entity or special fund under public law, Aachen shall be the exclusive place of jurisdiction. However, VSY is also entitled to sue the customer at his place of business.

18. Data

We are entitled to process data about the customer received with regard to or in connection with the business relationship, regardless of whether such data originates from the customer itself or from third parties, in compliance with the provisions of the Federal Data Protection Act. The invalidity of individual points of the contract with the customer does not affect the validity of the remaining provisions.

Leinfelden-Echterdingen, June 2021 - VSY Biotechnology GmbH

Page Link

/agb-en